|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||31.19 / 86.26|
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis' Rubraca ® (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers...
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2018, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the second half of 2018.
Is the pharma sector fever heating up in 2H18? Drug investors, get ready as there could be some good trades to be made.
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2018 financial results on Wednesday, August 1, 2018, after the close of the U.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Medicines Agency (EMA) has validated the application for a Type II variation to the marketing authorization for Rubraca ® (rucaparib) to include maintenance treatment of adult patients...
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the submission of a regulatory application to the European Medicines Agency (EMA), as part of a type II variation seeking to expand the marketing authorization for Rubraca (rucaparib) to include...
Jim Cramer weighs in on Groupon, Applied Materials, Adobe Systems, Cara Therapeutics, Watsco, CBRL Group, Pilgrim's Pride and more.
Global uncertainty, interest rates, and profit-taking are weighing on the markets. But Jim Cramer argues these events are good for the U.S.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic),...
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that seven abstracts highlighting progress in the Rubraca preclinical research and clinical development program will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting...
After a strong week for the biotech sector, these names have potential catalysts to move shares.
Presentation and webcast time listed in first paragraph of release should read: Wednesday, May 16, 2018 at 11:20 AM local time (instead of Thursday, May 17, 2018 at 10:00 AM Pacific Time).
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2018, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for 2018.
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2018 financial results on Tuesday, May 8, 2018, after the close of the U.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
A look at possible second-quarter M&A activity in the biotech sector.
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: GSM, RSPP, SVM, TDS Downgrades: AG, BGS, DJCO, EVC, GLRE, TCP Initiations: CLVS Read on to get TheStreet Quant Ratings' detailed report:
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the...
Your burning biotech questions answered in our latest mailbag.
We'll answer two of the common questions we have received so far in March.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the Company has received a Notice of Allowance from the United States Patent and Trademark Office in United States Patent Application 14/828,065 with claims...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.